应用CIK细胞治疗子宫内膜癌患者外周血T淋巴细胞亚群和NK细胞变化的临床观察

Clinical observation on the changes of T lymphocytes subgroups and NK cells in peripheral blood of patients with endometrial cancer treated with CIK cells

目的:观察应用细胞因子诱导杀伤细胞(cytokine-induced killer cells,CIK)联合化疗、内分泌治疗等治疗子宫内膜癌的临床疗效。方法:子宫内膜癌患者35例给予联合应用CIK细胞生物治疗6个疗程,其中11例患者TP(紫杉醇+顺铂)化疗联合CIK细胞生物治疗,15例患者醋酸甲地孕酮内分泌治疗联合CIK细胞生物治疗,9例患者单纯应用CIK细胞生物治疗。通过流式细胞术检测治疗前后患者T淋巴细胞亚群CD3+、CD4+、CD4+/CD8+比值以及NK细胞比例、KPS评分等指标变化,用统计学方法进行分析。结果:35例子宫内膜癌患者经联合CIK细胞生物治疗后,CD3+T细胞无显著变化,CD4+辅助T细胞显著增加,CD4+/CD8+比值显著升高,部分患者CD3-/CD16+56+的NK细胞较治疗前升高但无统计学意义,患者平均KPS评分提高10分(P<0.05)。结论:CIK细胞可以提高子宫内膜癌患者机体免疫功能,改善患者一般状态。

Objective：To observe the clinical efficacy of cytokine-induced killer（CIK） cells combined with chemotherapy,endocrine therapy for endometrial cancer.Methods：Thirty-five patients with endometrial cancer were treated with biotherapy of CIK cells for 6 courses of treatment,including 11 patients treated with chemotherapy（taxol and platinol） combined with biotherapy of CIK cells,15 patients treated with endocrine therapy of megestrol acetate combined with biotherapy of CIK cells,and 9 patients treated with simple biotherapy of CIK cells.The changes of CD3＋ lymphocytes subgroup,CD4＋ lymphocytes subgroup,the ratio of CD4＋/CD8＋,proportion of NK cells,and KPS scores before and after treatment were detected by flow cytometry,then the results were analyzed retrospectively.Results：After treatment,CD3＋ cells of 35 patients with endometrial cancer didn＇t change significantly,CD4＋ helper T lymphocytes increased significantly,the ratio of CD4＋/CD8＋ increased significantly,CD3-/CD16＋56＋ cells of some patients increased after treatment,but there was no statistically significant difference between before and after treatment,the mean KPS score after treatment increased by 10（P0.05）.Conclusion：CIK cells can improve the immune function and general status of patients with endometrial cancer.